The open index of psychedelic research

Therapeutic potential of psilocybin in the pharmacological treatment of obsessive-compulsive disorder: a scoping review protocol.

Treating addiction with an addictive drug: the ketamine paradox revisited.

Hakami AY

Esketamine for treatment-resistant depression: Comparing two maintenance schedules in an observational real-world study

Westenhöfer S, Ehrt Y, Provaznikova B +9

Psilocybin selectively rescues cognitive flexibility impairments caused by aberrant prefrontal error signaling

Liu C, Ho EM, Enos AS +4

Real-world outcomes of intranasal esketamine and intravenous ketamine induction therapy for treatment-resistant depression in a community clinic: a retrospective cohort study.

Bellanti PA, Lewis J, Seifferth B +1

Is there evidence that intranasal ketamine can provide adequate procedural sedation in paediatric patients?

Jeyabelen H, Manak I

Median Effective Dose of Esketamine Combined with Remifentanil for Anesthesia Induction in Painless Colonoscopy.

Cao Z, Xue H, Wang H +1

First molecular record of Panaeolus subbalteatus (Psathyrellaceae, Agaricales) from Pakistan.

Rukhsar S, Yousaf N, Sadaf +5

UK Practitioner Psychologists' Knowledge and Harm Assessment of Psychedelics: A Cross-Sectional Study

Psilocybin therapy for adult females with anorexia nervosa: pilot study.

Douglass HM, Spriggs MJ, Godfrey K +17

Psychedelics and Ibogaine "Pain Medications" at the Pharmacy Counter: Implications for Pharmacy Practice.

Breve F, Berenato FJ, Pergolizzi JV Jr +2

Beyond symptom reduction: DMT improves anxiety, life satisfaction, and quality of life in healthy volunteers and patients with depression.

Bolcont R, Palhano-Fontes F, Barros H +6

Efficacy and safety of perioperative esketamine for postoperative depressive symptoms in breast cancer patients: a meta-analysis.

Ji R, Shi X, Liu X +6

Combined Ketamine and Cognitive-Behavioral Therapy: Leveraging Metaplasticity to Enhance Treatment Outcomes.

Hardy MS, Li SW, Wilkinson ST

Chronic ketamine use associated with progressive multisystem organ dysfunction.

Mudgal C, Bodansky HJ

Association of esketamine exposure with secondary sclerosing cholangitis in critically ill patients: a retrospective cohort analysis of 20,000 ICU cases.

Zeiner S, Rettenbacher J, Nowak NM +8

Mechanisms of Action and Change in Psychedelic-Assisted Therapies: A Holistic Framework for Ethical, Competent Clinical Care.

Averill LA, Neitzke-Spruill L

Redefining the real problem in psychedelic trials: Why fighting the Lessebo matters more than blinding integrity.

Vanderijst L, Faillie JL, Mura T +1

α<sub>2</sub>-Adrenergic receptor modulates 5-HT<sub>2A</sub>-mediated behavioral effects of MDMA and psilocybin in mice.

Rosado AF, Yu AL, Yang JH +13

Making a case for using MDMA-assisted psychotherapy for borderline personality disorder and complex PTSD: a descriptive systematic review of the literature.

Kasiviswanathan K, Nilaweera D, Morando M +4

Association between Intravenous Ketamine Treatment and Cognitive Function in Patients with Treatment-Resistant Depression: A Double-Blind, Randomized, Placebo-Controlled Trial.

Nomoto K, Ohtani Y, Yatomi T +19

Ketamine harm reduction: Collaborative development of a prevention ecosystem using data from the northwest of England

Mughal R, Ryan-McNeill E, Mezes B +3

Use of Intravenous Lidocaine, Ketamine, and Magnesium for Acute Pain Control After Lung Resection Surgery: A Prospective Cohort Study.

Herrera J, Torres S, Diaz M +5

CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorder.

Paslawski W, Doyon D, Ekman CJ +9